Prognostic value of thymidine phosphorylase expression in breast carcinoma

International Journal of Cancer

Volumn 97, Issue 4, 2002, Pages 512-517

  Yang, Qifeng ^a   Barbareschi, Mattia ^b   Mori, Ichiro ^a   Mauri, Francesco ^a   Muscarà, Maurizio ^c   Nakamura, Misa ^a   Nakamura, Yasushi ^a   Yoshimura, Goro ^a   Sakurai, Takeo ^a   Caffo, Orazio ^b   Galligioni, Enzo ^b   Dalla Palma, Paolo ^b   Kakudo, Kennichi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b SANTA CHIARA HOSPITAL   (Italy)

^c Ospedale SS Trinita   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; Prognosis; Thymidine phosphorylase

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 654 1; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN P53; TAMOXIFEN; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LIFE TABLES; METHOTREXATE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL ANALYSIS; TAMOXIFEN; THYMIDINE PHOSPHORYLASE;

EID: 0036466862     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1633     Document Type: Article

References (42)

1. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy
2. Kinetic studies of thymidine phosphorylase from mouse liver
3. Purification and properties of an endothelial cell growth factor from human platelets
4. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor, Nature
5. Thymidine phosphorylase is angiogenic and promotes tumor growth
6. Angiogenic activity of enzymes
7. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis
8. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity
9. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study
10. Development and characterization of IC6-203, a new monoclonal antibody specific to human thymidine phosphorylase
11. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer
12. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast
13. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium
14. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast
15. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil
16. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase
17. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites
18. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA
19. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma
20. Relationship of elevated tumor thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF
21. Methotrexate cytotoxicity determination using the MTT assay following enzymatic depletion of thymidine and hypoxanthine
22. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: Experience from a large study with long term follow-up
23. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
24. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma
25. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
26. ER1D5 and H222 (ER-ICA) antibodies to human estrogen receptor protein in breast carcinomas. Results of a multicentric comparative study
27. Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. A review of the literature involving over 9000 patients
28. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues
29. Thymidine phosphorylase expression in invasive breast carcinoma: Correlations with clinicopathologic variables and in vitro sensitivity to 5-fluorouracil
30. Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells
31. Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase
32. Biomodulation of 5-fluorouracil by interferonalpha in human renal carcinoma cells: Relationship to the expression of thymidine phosphorylase
33. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes
34. Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor
35. Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha
36. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer
37. Enhancement of the antitumor effect of 5′-deoxy-5-fluorouridine by transfection of thymidine phosphorylase gene into human colon cancer cells
38. Increased cytotoxicity bystander effect of 5-fluorouracil 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase
39. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
40. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
41. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil
42. Correlation between expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) and microvessel density in early-stage human colon carcinomas